@DimLeb, thanks for answering. Let's hope your tinnitus gets better again.
It seems like Quercetin does not work so well for a lot of people on here. Maybe if one would take like a really high dose of Quercetin the effects would be more noticeable.
I don't know if this would answer your question, but the compound Prof. Tzounopoulos and his team uses is
RL648_81. Don't know if you checked it out already but you can read more about it
here.
Prof. Tzounopoulos conducted a study with this compound on mice last year. The conclusion of the study reads:
"The most important finding of our study is the wide time-window after noise exposure within which RL-81 can reduce the percentage of mice that show tinnitus. In previous reports, retigabine was administered 30 min and up to 4 days after the acoustic trauma/ hearing loss, and tinnitus was assessed by deficiencies in the gap detection reflex 7 days after noise exposure (Li et al. 2013, 2015). Patients, on the other hand, may not seek treatment immediately after the sudden onset of tinnitus. Therefore, it is crucial that the critical window during which KCNQ potentiation is effective against tinnitus is delineated in a validated animal model. Here, we validated and used an operant animal model of tinnitus, and showed that application of RL-81 even 7 days after noise exposure reduced the percentage of mice that showed tinnitus. Whereas 7 days is the minimum therapeutic window, it is optimistic for future clinical trials. However, more studies are needed to evaluate the full extent of this therapeutic window. Moreover, the duration of the therapeutic benefit following transient administration of RL-81, and whether RL-81 can mitigate tinnitus when assessed months after noise trauma remain to be determined. Finally, given that this potential treatment strategy might be feasible for military personnel exposed to extremely loud sounds, such as blast exposure, assessment of RL-81 in a blast-induced animal model of tinnitus could be beneficial. Evaluation of these parameters will be useful for selecting the most appropriate target population for subsequent clinical trials to assess RL-81 as a tinnitus treatment strategy" (pp. 136-137)
Marinos, L., Kouvaros, S., Bizup, B., Hambach, B., Wipf, P., & Tzounopoulos, T. (2021).
Transient delivery of a kcnq2/3-specific channel activator 1 week after noise trauma mitigates noise-induced tinnitus.
Journal of the Association for Research in Otolaryngology,
22(2), 127–139.
I could not figure out which compound XEN-1101 was.
The paper finishes on the following note:
"Combined with the increased chemical stability as a function of the fluorinated backbone structure in RL-81, RL-81 is less likely to exhibit the clinical pathology characteristic of retigabine. Further toxicology assessments and a transition to early clinical evaluation are therefore in progress" (p. 138).
I think we have very real reasons to be optimistic for this drug.
1. Prof. Tzounopoulos and his team seem to have enough funding for clinical trials.
2. Unlike XEN-1101, RL-81 is actually being tested on animals for tinnitus.
3. If I read the study correctly, RL-81 is more effective at preventing tinnitus from developing in mice after acoustic trauma in comparison to Retigabine.
4. RL-81 will likely have less adverse effects than Retigabine.
Member
